参考文献/References:
[1] Ristagno G,Fumagalli F,Bottazzi B,et al. Pentraxin 3 in cardiovascular disease[J]. Front Immunol,2019,10:823.
[2] Bottazzi B,Doni A,Garlanda C,et al. An integrated view of humoral innate immunity:pentraxins as a paradigm[J]. Annu Rev Immunol,2010,28:157-183.
[3] Shin MK,Choi B,Kim EY,et al. Elevated pentraxin 3 in obese adipose tissue promotes adipogenic differentiation by activating neuropeptide Y signaling[J]. Front Immunol,2018,9:1790.
[4] Nebuloni M,Pasqualini F,Zerbi P,et al. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis[J]. Cardiovasc Pathol,2011,20(1):e27-e35.
[5] Ketter P,Yu JJ,Cap AP,et al. Pentraxin 3:an immune modulator of infection and useful marker for disease severity assessment in sepsis[J]. Expert Rev Clin Immunol,2016,12(5):501-507.
[6] Moalli F,Doni A,Deban L,et al. Role of complement and Fc{gamma} receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus[J]. Blood,2010,116(24):5170-5180.
[7] Chorny A,Casas-Recasens S,Sintes J,et al. The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells[J]. J Exp Med,2016,213(10):2167-2185.
[8] Porte R,Davoudian S,Asgari F,et al. The long pentraxin PTX3 as a humoral innate immunity functional player and biomarker of infections and sepsis[J]. Front Immunol,2019,10:794.
[9] Liu H,Jiang Q,Ju Z,et al. Pentraxin 3 promotes cardiac differentiation of mouse embryonic stem cells through JNK signaling pathway[J]. Cell Biol Int,2018,42(11):1556-1563.
[10] Zhao Y,Feng G,Wang Y,et al. A key mediator,PTX3,of IKK/IκB/NF-κB exacerbates human umbilical vein endothelial cell injury and dysfunction[J]. Int J Clin Exp Pathol,2014,7(11):7699-7707.
[11] Luo XY,Zhu XQ,Li Y,et al. MicroRNA-150 restores endothelial cell function and attenuates vascular remodeling by targeting PTX3 through the NF-κB signaling pathway in mice with acute coronary syndrome[J]. Cell Biol I nt,2018,42(9):1170-1181.
[12] Balhara J,Shan L,Zhang J,et al. Pentraxin 3 deletion aggravates allergic inflammation through a T17-dominant phenotype and enhanced CD4 T-cell survival[J]. J Allergy Clin Immunol,2017,139(3):950-963.e9.
[13] Zlibut A,Bocsan IC,Agoston-Coldea L. Pentraxin-3 and endothelial dysfunction[J]. Adv Clin Chem,2019,91:163-179.
[14] Bonacina F,Barbieri SS,Cutuli L,et al. Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation[J]. Biochim Biophys Acta,2016,1862(6):1182-1190.
[15] Shimizu T,Suzuki S,Sato A,et al. Cardio-protective effects of pentraxin 3 produced from bone marrow-derived cells against ischemia/reperfusion injury[J]. J Mol Cell Cardiol,2015,89(Pt B):306-313.
[16] de Oliveira THC,Souza DG,Teixeira MM,et al. Tissue dependent role of PTX3 during ischemia-reperfusion injury[J]. Front Immunol,2019,10:1461.
[17] Casula M,Montecucco F,Bonaventura A,et al. Update on the role of pentraxin 3 in atherosclerosis and cardiovascular diseases[J]. Vascul Pharmacol,2017,99:1-12.
[18] 林朴卿,齐悦,张良珍,等. 血浆CPP、PTX3水平对稳定性冠心病患者冠状动脉狭窄的诊断价值[J]. 山东医药,2020,60(10):27-31.
[19] Cao RY,Yang J,Zheng Y,et al. The potential value of Copeptin and Pentraxin3 for evaluating the severity of coronary stenosis in patients with coronary artery disease[J]. Clin Biochem,2021,87:32-38.
[20] Conte E,Andreini D,Magnoni M,et al. Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers:insight from CAPIRE study[J]. J Cardiovasc Comput Tomogr,2021,15(1):73-80.
[21] Kimura S,Sugiyama T,Hishikari K,et al. Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris[J]. Atherosclerosis,2020,292:127-135.
[22] Lee R,Ahn HR,Shin MH,et al. Association of plasma pentraxin-3 level with lipid levels and cardiovascular risk factors in people with no history of lipid-lowering medication:the Dong-gu Study[J]. J Atheroscler Thromb,2019,26(8):738-745.
[23] Tojo M,Shintani-Ishida K,Tsuboi H,et al. Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome[J]. Sci Rep,2019,9(1):8090.
[24] Demir MT,Baydin A,Amanvermez R,et al. Comparison of pentraxin-3 and ischemia-modified albumin with troponin in early diagnosis of acute coronary syndrome[J]. Bratisl Lek Listy,2018,119(8):509-512.
[25] George M,Shanmugam E,Srivatsan V,et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome:a short-term prospective cohort study[J]. Ther Adv Cardiovasc D is,2015,9(5):275-284.
[26] Mjelva ?R,P?nitz V,Brügger-Andersen T,et al. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome[J]. Eur J Prev C ardiol,2016,23(11):1130-1140.
[27] Kontny F,Andersen T,Ueland T,et al. Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome:a substudy of the Platelet Inhibition and Patients Outcomes(PLATO) trial[J]. Eur Heart J Acute Cardiovasc Care, 2020,9(4):313-322.
[28] Chu Y,Teng J,Feng P,et al. Pentraxin-3 in coronary artery disease:a meta-analysis[J]. Cytokine,2019,119:197-201.
[29] Fornai F,Carrizzo A,Forte M,et al. The inflammatory protein Pentraxin 3 in cardiovascular disease[J]. Immun Ageing,2016,13(1):25.
[30] Alipour-Parsa S,Haybar H,Namazi MH,et al. Evaluation of pentraxin-3 level and its related factors in patients undergoing primary percutaneous coronary intervention[J]. ARYA Atheroscler,2017,13(2):73-78.
[31] Khamitova AF,Lakman IA,Akhmetvaleev RR,et al. Multifactor predictive model in patients with myocardial infarction based on modern biomarkers[J]. Kardiologiia,2020,60(3):14-20.
[32] Altay S,?akmak HA,Kemalo?lu ?z T, et al. Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction:5-year prospective cohort study[J]. Anatol J Cardiol,2017,17(3):202-209.
[33] Vukovi? Dejanovi? V,Bogavac-Stanojevi? N,Kotur Stevuljevi? J,et al. Circulating levels of inflammatory parameters pentraxin-3,cyclophilin and heparin-binding epidermal growth factor-like growth factor in patients with ST-elevation myocardial infarction[J]. Scand J Clin Lab Invest,2020,80(1):66-72.
[34] Tomandlova M,Jarkovsky J,Tomandl J,et al. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress[J]. Dis Markers,2015,2015:159051.
[35] Dharma S,Sari NY,Santoso A,et al. Association of plasma pentraxin 3 concentration with angiographic and clinical outcomes in patients with acute ST-segment elevation myocardial infarction treated by primary angioplasty[J]. Catheter Cardiovasc Interv,2020,96(6):1233-1239.
[36] Ljuca F,Had?iefendi? B,Jahi? E,et al. Pentraxin 3 might be better prognostic serum marker than IL-6,IL-10,and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation[J]. Saudi Med J,2019,40(12):1202-1208.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(11):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(11):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(11):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(11):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(11):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(11):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(11):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(11):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]